Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Weiner

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Expert Opinion on Pharmacotherapy|November 5, 2003
Alfuzosin for the management of benign prostate hyperplasiaDavid M Weiner, Franklin C Lowe
Hematology/Oncology Clinics of North America|July 30, 2024
Cutaneous T-cell LymphomaDavid M Weiner, Alain H Rook
The Journal of Biological Chemistry|November 7, 2003
RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoformsSébastien Marion, David M Weiner, Marc G Caron
Journal of the American Academy of Dermatology|December 22, 2020
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approachesDavid M Weiner, Joseph S Durgin, Maria Wysocka, et al.
Journal of the American Academy of Dermatology|December 22, 2020
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradicationJoseph S Durgin, David M Weiner, Maria Wysocka, et al.
The Journal of Biological Chemistry|January 22, 2002
Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6David A Shapiro, Kurt Kristiansen, David M Weiner, et al.
Molecular Pharmacology|February 24, 2004
Loss-of-function polymorphic variants of the human angiotensin II type 1 receptorJakob Lerche Hansen, Stig Haunsø, Mark R Brann, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|November 19, 2003
Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeuticsDavid M Weiner, Kimberly E Vanover, Mark R Brann, et al.
Urology Case Reports|January 25, 2021
Silicone injection-induced granuloma formation, hypercalcemia and nephrolithiasis: a case reportAlbert S Ha, Rainjade Chung, Samantha Thorogood, et al.
Sleep Medicine|January 25, 2011
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteersSonia Ancoli-Israel, Kimberly E Vanover, David M Weiner, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|November 5, 2003
Alfuzosin for the management of benign prostate hyperplasiaDavid M Weiner, Franklin C Lowe
Hematology/Oncology Clinics of North America|July 30, 2024
Cutaneous T-cell LymphomaDavid M Weiner, Alain H Rook
The Journal of Biological Chemistry|November 7, 2003
RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoformsSébastien Marion, David M Weiner, Marc G Caron
Journal of the American Academy of Dermatology|December 22, 2020
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approachesDavid M Weiner, Joseph S Durgin, Maria Wysocka, et al.
Journal of the American Academy of Dermatology|December 22, 2020
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradicationJoseph S Durgin, David M Weiner, Maria Wysocka, et al.
The Journal of Biological Chemistry|January 22, 2002
Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6David A Shapiro, Kurt Kristiansen, David M Weiner, et al.
Molecular Pharmacology|February 24, 2004
Loss-of-function polymorphic variants of the human angiotensin II type 1 receptorJakob Lerche Hansen, Stig Haunsø, Mark R Brann, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|November 19, 2003
Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeuticsDavid M Weiner, Kimberly E Vanover, Mark R Brann, et al.
Urology Case Reports|January 25, 2021
Silicone injection-induced granuloma formation, hypercalcemia and nephrolithiasis: a case reportAlbert S Ha, Rainjade Chung, Samantha Thorogood, et al.
Sleep Medicine|January 25, 2011
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteersSonia Ancoli-Israel, Kimberly E Vanover, David M Weiner, et al.
Pageof 4